EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+13.11%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$933M
AUM Growth
+$933M
(+25%)
Cap. Flow
+$92.4M
Cap. Flow
% of AUM
9.9%
Top 10 Holdings %
Top 10 Hldgs %
79.57%
Holding
39
New
10
Increased
7
Reduced
7
Closed
7
Top Buys
| 1 |
Arcus Biosciences
RCUS
|
$34.5M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$21.3M |
| 3 |
Wave Life Sciences
WVE
|
$21M |
| 4 |
UroGen Pharma
URGN
|
$20M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$14.1M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$32.8M |
| 2 |
Ascendis Pharma
ASND
|
$18.6M |
| 3 |
Galapagos
GLPG
|
$10.4M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$8.18M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$4.21M |
Sector Composition
| 1 | Healthcare | 93.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Assembly Biosciences
ASMB
$190M
| $145M | 14.51% | 2,943,165 +1 | +0% | +$49 |
|
|
2
Ascendis Pharma
ASND
$11.8B
| $119M | 11.96% | 1,822,575 -285,025 | -14% | -$18.6M |
|
3
FibroGen
FGEN
$47.8M
| $92.5M | 9.28% | 2,002,437 -45,300 | -2% | -$2.09M |
|
4
Ironwood Pharmaceuticals
IRWD
$214M
| $90.8M | 9.11% | 5,885,583 | – | – |
|
5
Kura Oncology
KURA
$686M
| $70.6M | 7.08% | 3,766,852 | – | – |
|
|
6
Wave Life Sciences
WVE
$1.53B
| $58.5M | 5.87% | 1,459,072 +522,909 | +56% | +$21M |
|
|
ARRY
7
DELISTED
Array Biopharma Inc
ARRY
| $49.8M | 4.99% | 3,049,312 +166,600 | +6% | +$2.72M |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $45.5M | 4.57% | 4,764,447 -72,100 | -1% | -$689K |
|
9
MacroGenics
MGNX
$112M
| $36.5M | 3.66% | 1,450,606 +309,812 | +27% | +$7.79M |
|
|
10
Arcus Biosciences
RCUS
$1.13B
| $34.5M | 3.46% | +2,236,387 | New | +$34.5M |
|
11
Apellis Pharmaceuticals
APLS
$3.48B
| $23.4M | 2.34% | 1,056,348 -88,210 | -8% | -$1.95M |
|
|
FPRX
12
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $21.3M | 2.14% | +1,240,470 | New | +$21.3M |
|
|
13
UroGen Pharma
URGN
$900M
| $20M | 2.01% | +402,300 | New | +$20M |
|
|
IMDZ
14
DELISTED
Immune Design Corp.
IMDZ
| $14.4M | 1.45% | 4,437,600 +875,000 | +25% | +$2.84M |
|
|
15
Agios Pharmaceuticals
AGIO
$2.19B
| $14.1M | 1.42% | +172,952 | New | +$14.1M |
|
16
Akebia Therapeutics
AKBA
$833M
| $13.6M | 1.36% | +1,425,000 | New | +$13.6M |
|
|
ACHN
17
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $13.6M | 1.36% | 3,668,307 +1,827,582 | +99% | +$6.76M |
|
|
DOVA
18
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $11.7M | 1.17% | +429,729 | New | +$11.7M |
|
|
ATYR
19
aTyr Pharma
ATYR
$527M
| $10.6M | 1.06% | 3,917,972 | – | – |
|
|
DBVT
20
DBV Technologies
DBVT
$264M
| $10.4M | 1.04% | +450,000 | New | +$10.4M |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $9.31M | 0.93% | +1,083,567 | New | +$9.31M |
|
22
Synlogic
SYBX
$17M
| $6.57M | 0.66% | +700,000 | New | +$6.57M |
|
23
Denali Therapeutics
DNLI
$2.23B
| $6.4M | 0.64% | 325,000 +125,000 | +63% | +$2.46M |
|
|
24
Rhythm Pharmaceuticals
RYTM
$6.85B
| $6.34M | 0.64% | 318,564 -211,597 | -40% | -$4.21M |
|
25
Corvus Pharmaceuticals
CRVS
$428M
| $5.42M | 0.54% | 469,700 -118,732 | -20% | -$1.37M |
|